ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointment of Richard Douglas, Ph.D. to its board of directors. Dr. Douglas is currently Senior Vice President, Corporate Development at Genzyme Corp. As a leader of Genzyme's Corporate Development team, Dr. Douglas has been involved in numerous acquisitions, licenses, joint ventures and strategic alliances as well as Genzyme's venture investments. He has served in a variety of corporate and product development positions with Genzyme since he joined Integrated Genetics (now Genzyme) as a staff scientist in 1982.
Novavax Chairman Stanley Erck stated: "Richard has more than twenty-five years of corporate, business and product development experience at Genzyme which will be extremely valuable to Novavax as we advance our vaccine candidates. His expertise in business development, technology assessment and protein chemistry will be especially helpful in guiding our future discovery, development and commercialization programs. We welcome his counsel and contributions to our future success."
Dr. Douglas currently serves on the national advisory board of the University of Michigan Technology Transfer Office and previously served as a director of Iomai Corporation and Synthon Chiragenics. He received his doctorate in biochemistry from the University of California at Berkeley and his bachelor's degree in chemistry from the University of Michigan.
|SOURCE Novavax, Inc.|
Copyright©2010 PR Newswire.
All rights reserved